drugset / Trial / NCT07641010
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
RandomizedParallel-groupOpen-labelTreatment
Summary
A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
Timeline
- Start
- 2026-06-30
- Primary completion
- 2028-09-30
- Completion
- 2030-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | SHR0302 | Unknown | 4 mg/m2 | Oral |